Policy Developments - The National Medical Products Administration (NMPA) has released multiple registration review guidelines for cancer screening in vitro diagnostic reagents, aiming to further standardize the management of these products [1] Medical Device Approvals - Sinno Medical announced that its subsidiary received a medical device registration certificate for a disposable microcatheter, which will enhance its product portfolio in the neurointerventional sector [2] - Heng Rui Medicine received approval for clinical trials of HRS-6093 tablets, a novel oral KRASG12D inhibitor, and HRS-2162 injection, a new generation muscle relaxant antagonist, both of which currently have no similar products approved in the market [3] - Mayinglong's subsidiary obtained a drug registration certificate for Olopatadine Hydrochloride eye drops, used for treating allergic conjunctivitis [4] Financial Reports - Xiaofang Pharmaceutical reported a 3.06% year-on-year increase in revenue to 270 million yuan and a 1.69% increase in net profit to 121 million yuan for the first half of the year [5] - Renhe Pharmaceutical's revenue decreased by 16.46% to 1.975 billion yuan, with a net profit decline of 13.87% to 290 million yuan for the same period [6] - China National Pharmaceutical Group announced a revenue of 286 billion yuan and an operating profit of 7.45 billion yuan for the first half of the year, with a gross margin of 7.11% [7] Capital Market Activities - BeiGene entered into a royalty purchase agreement with Royalty Pharma, agreeing to pay $885 million for the rights to a significant portion of royalties from the monoclonal antibody Imdelltra outside of China [9] - Terumo Corporation announced a $1.5 billion acquisition of OrganOx to expand its presence in the transplant medicine sector, focusing on liver preservation technology [10] Industry Developments - A domestic team has successfully utilized brain-computer interface technology for precise diagnosis and treatment of hydrocephalus, significantly reducing diagnosis time from 2-3 days to 30 minutes, marking a breakthrough in the application of this technology [11] - Sailun Biotech has launched its rabies serum product for sale in several provinces, becoming the only company to market this product [12] Corporate News - Yifeng Pharmacy announced the resignation of its Vice President, Zhang Jia, due to personal reasons [13]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性 亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致 之任何損失承擔任何責任。 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條作出。 以下公告的中文原稿將由國藥控股股份有限公司於 2025 年 8 月 25 日於中國貨幣網網站 (http://www.chinamoney.com.cn)及上海清算所網站(http://www.shclearing.com.cn)發佈，僅供參閲。 承董事會命 國藥控股股份有限公司 董事長 趙炳祥 中國，上海 2025 年 8 月 25 日 於本公告日期，執行董事為連萬勇先生及孫京林先生；非執行董事為趙炳祥先生、陳啟宇先生、祖敬先 生、邢永剛先生、陳玉卿先生、文德鏞先生及馮蓉麗女士；獨立非執行董事為李培育先生、吳德龍先生、 俞衛鋒先生、石晟昊先生及陳威如先生。 * 本公司以其中文名稱及英文名稱「 Sinopharm Group Co. Ltd. 」根據香港公司條例註冊為非香港公司。 25 重要提示 发行人承诺将及时、公 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性 亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致 之任何損失承擔任何責任。 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條作出。 以下公告的中文原稿將由國藥控股股份有限公司於 2025 年 8 月 25 日於上海證券交易所網站 (http://www.sse.com.cn)發佈，僅供參閲。 承董事會命 國藥控股股份有限公司 董事長 趙炳祥 中國，上海 2025 年 8 月 25 日 於本公告日期，執行董事為連萬勇先生及孫京林先生；非執行董事為趙炳祥先生、陳啟宇先生、祖敬先 生、邢永剛先生、陳玉卿先生、文德鏞先生及馮蓉麗女士；獨立非執行董事為李培育先生、吳德龍先生、 俞衛鋒先生、石晟昊先生及陳威如先生。 * 本公司以其中文名稱及英文名稱「 Sinopharm Group Co. Ltd. 」根據香港公司條例註冊為非香港公司。 2025年6月30 (除特别注明外,金额单位 | | 2025年6月30日 | 2024年12月31日 | | --- | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性 亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致 之任何損失承擔任何責任。 中國，上海 2025 年 8 月 25 日 於本公告日期，執行董事為連萬勇先生及孫京林先生；非執行董事為趙炳祥先生、陳啟宇先生、祖敬先 生、邢永剛先生、陳玉卿先生、文德鏞先生及馮蓉麗女士；獨立非執行董事為李培育先生、吳德龍先生、 俞衛鋒先生、石晟昊先生及陳威如先生。 * 本公司以其中文名稱及英文名稱「 Sinopharm Group Co. Ltd. 」根據香港公司條例註冊為非香港公司。 海外監管公告 国药控股股份有限公司 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條作出。 公司债券中期报告 以下公告的中文原稿將由國藥控股股份有限公司於 2025 年 8 月 25 日於上海證券交易所網站 (http://www.sse.com.cn)發佈，僅供參閲。 承董事會命 國藥控股股份有限公司 董事長 趙炳祥 （2025 年） 二〇二五年八月 0 国药控股股份有限公司公司债券中期报告（202 ...

Stock Market Performance - The Hang Seng Index rose 234 points or 0.9% to close at 25,339 points, the China Enterprises Index rose 105 points or 1.2% to close at 9,079 points, and the Hang Seng Tech Index rose 149 points or 2.7% to close at 5,647 points. The total turnover of the market was HK$285.584 billion [1]. - The Shanghai Composite Index rose 54 points or 1.45% to close at 3,825 points, the Shenzhen Component Index rose 246 points or 2.07% to close at 12,166 points, and the ChiNext Index rose 87 points or 3.36% to close at 2,682 points. The total turnover of the Shanghai and Shenzhen stock markets increased to approximately RMB2.55 trillion, setting a record for the A-share market [2]. - The Dow Jones Industrial Average and the Nasdaq Composite both rose 1.9%, the Dow Jones Industrial Average reached a new high, closing 846 points higher at 45,631 points, the Nasdaq Composite rose 396 points to 21,496 points, and the S&P 500 Index closed 96 points or 1.5% higher at 6,466 points, approaching last week's high [2]. Monetary Policy - The People's Bank of China conducted a seven-day reverse repurchase operation of RMB253 billion in the open market on the 21st, with an operating interest rate remaining flat at 1.4%. There were RMB128.7 billion of reverse repurchases due, resulting in a net injection of RMB124.3 billion [2]. - The central parity rate of the RMB against the US dollar was raised by 97 points to 7.1287 [2]. Trade Policy - Canada announced on Friday the cancellation of several countervailing tariffs against the US but maintained a 25% tariff on US automobiles, steel, and aluminum. The policy adjustment will take effect on September 1st [3]. Company Announcements IPO - Aux Group (02580.HK) plans to globally issue 207.16 million shares, with 5% (approximately 10.3582 million shares) for the Hong Kong public offering and 95% (approximately 196.8 million shares) for the international placement. The offering price ranges from HK$16 to HK$17.42 per share, with a maximum fundraising of approximately HK$3.61 billion. The subscription period is from the 25th to noon on the 28th, and it is expected to be listed on September 2nd [4]. Interim Results - Sinopharm Group (01099.HK) reported a turnover of RMB286.043 billion for the six months ended June 30th, a year-on-year decrease of 2.9%. The net profit was RMB3.466 billion, a year-on-year decrease of 6.4%, and the earnings per share were RMB1.11. No dividend was declared [4]. - Zhaojin Mining Industry (01818.HK) reported an income of RMB6.972 billion for the six months ended June 30th, a year-on-year increase of 50.7%. The gross profit was RMB3.05 billion, an increase of 54.3%. The net profit was RMB1.44 billion, a growth of 160.4%, and the earnings per share were RMB0.38. No dividend was declared [4]. - Greentown China (03900.HK) reported an income of RMB53.368 billion for the six months ended June 30th, a year-on-year decrease of 23.3%, due to a 22.7% decrease in the transfer area during the period. The gross profit was RMB7.159 billion, a decrease of 21.4%. The net profit was RMB210 million, a decline of 89.7%, mainly affected by an impairment loss of RMB1.933 billion on related assets. The earnings per share were RMB0.08. No dividend was declared [5]. - Chow Tai Fook Jewellery Group (06168.HK) reported an income of RMB3.15 billion for the six months ended June 30th, a year-on-year increase of 5.2%. The gross profit was RMB827 million, an increase of 8.7%, mainly due to the contribution of the self - operated business model. The net profit was RMB415 million, a growth of 11.9%, and the earnings per share were RMB1.09. An interim dividend of HK$0.45 was declared [5]. - Nine Masts Catering Group (09922.HK) reported an income of RMB2.753 billion for the six months ended June 30th, a year-on-year decrease of 10.1%. The net profit was RMB60.69 million, a decline of 16%, and the earnings per share were RMB0.04. No dividend was declared [5]. - CMOC Group (03993.HK) reported an operating income of RMB94.773 billion for the six months ended June 30th, a year-on-year decrease of 7.8%. The operating cost was RMB74.727 billion, a decrease of 11%. The net profit attributable to shareholders was RMB8.671 billion, a growth of 60.1%, setting a new high for the same period. The earnings per share were RMB0.41. No dividend was declared [5]. - CRRC Corporation Limited (01766.HK) reported an operating income of RMB119.758 billion for the six months ended June 30th, a year-on-year increase of 33%, mainly due to the growth of railway equipment and new industry revenues. The net profit was RMB7.246 billion, a growth of 72.5%, and the earnings per share were RMB0.25. An interim dividend of RMB0.11 was declared [6]. - Dongfang Selection (01797.HK) reported a total revenue of RMB4.392 billion for the fiscal year ended May 31st, a year-on-year decrease of 37.9%. The net profit was RMB5.74 million, a decline of 99.7%, and the earnings per share were RMB0.01. No dividend was declared. The net profit from continuing operations was RMB6.2 million, compared with RMB249 million in 2024. Excluding the financial impact of the sale of Yuhui Tongxing, the net profit from continuing operations was RMB135 million, a growth of 30%. The total operating cost of continuing operations decreased by 38.2% to RMB3 billion, mainly due to the decrease in the inventory cost and logistics cost of self - operated products caused by the decrease in GMV. The gross profit from continuing operations decreased by 17% to RMB1.4 billion, and the gross profit margin increased from 25.9% to 32% [7]. - China National Tobacco Hong Kong (06055.HK) reported an income of RMB10.316 billion for the six months ended June 30th, a year-on-year increase of 18.5%. The gross profit was RMB946 million, a decrease of 1.8%. The net profit was RMB706 million, a growth of 9.8%, and the earnings per share were RMB1.02. An interim dividend of HK$0.19 was declared, compared with HK$0.15 in the same period last year [7].

国药控股发布2025年中期业绩，报告期内，公司实现收入2860.43亿元人民币，同比下降2.95%；归属于 母公司股东的溢利为34.66亿元，同比减少6.43%；每股盈利1.11元。 面对市场变化，公司在加强合规和风险管控的同时，聚焦业务复苏，持续改善经营指标。医药分销板块 保持稳定，收入占比为73.62%；器械分销收入有所下降，占比为19.22%；医药零售板块实现逆势增 长，占比为5.78%。 报告期内，公司费用管控成效显著，销售、管理和财务费用率均有所下降，合计优化0.2个百分点，有 力支撑了利润的稳定。 ...

上半年，顺应新的行业环境和政策监管要求，本集团积极挖掘渠道协同和衍生服务的业务增长动能，进 一步树立价值驱动理念，加强盈利能力和现金回款等核心业务指标考核，各主要板块业务收入的同比增 速呈现差异化表现。其中，医药分销板块基本维持稳定发展，板块收入占比同比下降0.48个百分点，达 到73.62%;器械分销收入规模有所下降，板块收入占比同比略升0.08个百分点，达到19.22%;医药零售板 块呈现逆势增长态势，板块收入占比同比增长0.36个百分点，为5.78%。 2025年上半年，面对快速变化的政策和市场环境，本集团在董事会和管理层坚实领导下，在加强合规管 理及合理管控风险的同时，聚焦业务的稳定复苏，持续改善各项经营指标，着力打造新环境下业务可持 续发展的能力。 报告期内，本集团费用管控成效凸显，受益于融资成本降低、一体化管控举措和业务成本的下降，销售 费用率、管理费用率及财务费用率持续下降，分别为2.74%、1.28%和0.35%，三项费用率合计优化0.2个 百分点，为收窄利润下降提供有力支撑。 国药控股(01099)发布2025年中期业绩，该集团取得收入人民币2860.43亿元(单位下同)，同比减少2.95% ...

Core Viewpoint - The company reported a decline in revenue and profit for the first half of 2025, indicating challenges in the current market environment while focusing on sustainable business development and compliance management [1] Group 1: Financial Performance - The company achieved revenue of RMB 286.04 billion, a year-on-year decrease of 2.95% [1] - Profit attributable to shareholders was RMB 3.466 billion, down 6.43% year-on-year [1] - Earnings per share stood at RMB 1.11 [1] Group 2: Business Segments - The pharmaceutical distribution segment maintained stable development, with a revenue share decrease of 0.48 percentage points to 73.62% [1] - The medical device distribution segment saw a slight increase in revenue share by 0.08 percentage points to 19.22% despite a decline in revenue scale [1] - The pharmaceutical retail segment experienced growth, with a revenue share increase of 0.36 percentage points to 5.78% [1] Group 3: Cost Management - The company demonstrated effective cost control, benefiting from reduced financing costs and integrated management measures [2] - The sales expense ratio, management expense ratio, and financial expense ratio decreased to 2.74%, 1.28%, and 0.35% respectively, collectively optimizing by 0.2 percentage points [2]

报告期内，集团费用管控成效凸显，受益于融资成本降低、一体化管控举措和业务成本的下降，销售费 用率、管理费用率及财务费用率持续下降，分别为2.74%、1.28%和0.35% ，三项费用率合计优化0.2个 百分点，为收窄利润下降提供有力支撑。 格隆汇8月25日丨国药控股(01099.HK)发布公告，2025年上半年，集团实现营业收入人民币2860.43亿 元，较去年同期下降2.95%；净利润及归母净利润分别为人民币53.37亿元及34.66亿元，同比下降分别 为9.53%及6.43%。上半年，顺应新的行业环境和政策监管要求，集团积极挖掘渠道协同和衍生服务的 业务增长动能，进一步树立价值驱动理念，加强盈利能力和现金回款等核心业务指标考核，各主要板块 业务收入的同比增速呈现差异化表现。其中，医药分销板块基本维持稳定发展，板块收入占比同比下降 0.48个百分点，达到73.62%；器械分销收入规模有所下降，板块收入占比同比略升0.08个百分点，达到 19.22%；医药零售板块呈现逆势增长态势，板块收入占比同比增长0.36个百分点，为5.78%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 SINOPHARM GROUP CO. LTD. * （於中華人民共和國註冊成立之股份有限公司， 在香港以國控股份有限公司之名稱經營業務） （股份代號：01099） 二零二五年中期業績公告 國藥控股股份有限公司（「本公司」、「公司」或「國藥控股」）董事會（「董事會」）欣然宣佈本 公司及其附屬公司（「本集團」）截至二零二五年六月三十日止六個月期間（「報告期間」或 「報告期」）之未經審核中期業績，連同去年同期的比較資料如下： * 本公司以其中文名稱及英文名稱「Sinopharm Group Co. Ltd.」根據香港公司條例註冊為非香 港公司。 - 1 - 中期簡明綜合損益表 截至二零二五年六月三十日止六個月 | | | 截至六月三十日止六個月 | | | --- | --- | --- | --- | | | 附註 | 二零二五年 | 二零二四年 | | | | 人民幣千元 | 人民幣千元 | | | | ...